Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment

Trial Profile

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Molindone (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Acronyms CHIME 4
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 18 Sep 2017 According to Supernus media release, enrollment in the study continues to be very encouraging at a high level of 90%.
    • 13 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 02 Mar 2016 According to Supernus media release, company has finalized the special protocol assessment (SPA) with the FDA for this trial and data from this trial is expected by mid-2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top